Last reviewed · How we verify
Other approved anti-cancer therapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Other approved anti-cancer therapy (Other approved anti-cancer therapy) — Riboscience, LLC..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Other approved anti-cancer therapy TARGET | Other approved anti-cancer therapy | Riboscience, LLC. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Other approved anti-cancer therapy CI watch — RSS
- Other approved anti-cancer therapy CI watch — Atom
- Other approved anti-cancer therapy CI watch — JSON
- Other approved anti-cancer therapy alone — RSS
Cite this brief
Drug Landscape (2026). Other approved anti-cancer therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/other-approved-anti-cancer-therapy. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab